DCM
OVID icon

Delpha Capital Management’s Ovid Therapeutics OVID Stock Holding History

Delpha Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-314
Closed -$3K – 895
2017
Q4 		$3K Buy
+314
New +$2.88K ﹤0.01% 1427

Other funds holding OVID

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Delpha Capital Management's OVID Position: Q1 2018 in Review

Delpha Capital Management sold out of Ovid Therapeutics (OVID) in Q1 2018, closing a stake of 314 shares — an estimated $3K sold.

Delpha Capital Management first reported a position in OVID in Q4 2017 and held it in 1 quarter. The position peaked at $3K in Q4 2017. 48 funds tracked by Wall St. Rank hold OVID as of Q1 2018.

  • Delpha Capital Management reported no remaining Ovid Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 314 Ovid Therapeutics shares in Q1 2018, an estimated $3K.
  • Delpha Capital Management first reported a position in Ovid Therapeutics in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Ovid Therapeutics position peaked at $3K in Q4 2017.
  • 48 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.